File Thomas M
Northeastern Ohio Universities College of Medicine, Rootstown, OH; Infectious Disease Service, Summa Health System, Akron, OH, USA.
Int J Antimicrob Agents. 2007 Dec;30 Suppl 2:S131-4. doi: 10.1016/j.ijantimicag.2007.07.038.
Rising levels of resistance amongst the major respiratory pathogens have compromised empiric antimicrobial therapy. This, coupled with a recent lack in availability of novel classes of antibacterials, has led to a need for new approaches to combat community respiratory tract infections. Bacteriological and clinical efficacy in two trials involving patients with acute bacterial sinusitis and six trials of patients with community-acquired pneumonia has shown that the development of a pharmacokinetically enhanced formulation of amoxicillin/clavulanate (Augmentin SR, available as Augmentin XR in the USA) has allowed amoxicillin/clavulanate to retain its place in the treatment of respiratory tract infections today.
主要呼吸道病原体耐药性的不断上升，已使经验性抗菌治疗受到影响。再加上近期新型抗菌药物缺乏，因此需要新的方法来对抗社区呼吸道感染。在两项针对急性细菌性鼻窦炎患者的试验以及六项针对社区获得性肺炎患者的试验中，细菌学和临床疗效表明，阿莫西林/克拉维酸的药代动力学增强制剂（Augmentin SR，在美国以Augmentin XR名称上市）的研发，使阿莫西林/克拉维酸在如今的呼吸道感染治疗中仍占有一席之地。
